Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Abstract

Our results highlight the rarity of second tumors and provide a framework for defining clonal relationships and viral vector monitoring. (Funded by the National Cancer Institute and others.).